Description
About the CJC-1295 No DAC and Ipamorelin blend
Velora Research’s CJC-1295 No DAC plus Ipamorelin blend pairs two of the most extensively studied growth-hormone-axis research peptides in a single pre-formulated vial. The vial contains 5mg of CJC-1295 No DAC (also known as Modified GRF 1-29) and 5mg of Ipamorelin (10mg combined), lyophilized together for in vitro and preclinical investigation by qualified laboratories and research professionals.
The two compounds belong to different functional classes. CJC-1295 No DAC is a stabilized growth-hormone-releasing hormone (GHRH) analog that acts on the GHRH receptor. Ipamorelin is a selective ghrelin receptor agonist that acts on a separate receptor system. Pairing them in a 1:1 ratio is the most commonly cited configuration in published research investigating the additive characteristics of GHRH and ghrelin-receptor signaling. Velora’s blend supplies both compounds in one vial so researchers can run protocols that depend on this fixed ratio without separately reconstituting two compounds.
What is CJC-1295 No DAC?
CJC-1295 No DAC is a synthetic peptide analog of human growth-hormone-releasing hormone (GHRH). It is also referred to in research literature as Modified GRF 1-29 (ModGRF 1-29). The compound is a 30-amino-acid sequence derived from the first 29 amino acids of native GHRH, with four amino-acid substitutions (positions 2, 8, 15, and 27) that improve resistance to enzymatic degradation.
The ‘No DAC’ qualifier is important. CJC-1295 exists in two research forms. The DAC version carries a maleimide-linker drug-affinity complex that binds to plasma albumin, extending its functional half-life to several days. The No DAC version omits the linker, which produces a much shorter functional half-life (approximately 30 minutes in published data). Shorter signaling is preferred for research protocols that aim to model the natural pulsatile pattern of GHRH release rather than continuous receptor activation.
CJC-1295 No DAC is not approved by the FDA for any therapeutic indication. Velora’s product is supplied solely as a research compound for in vitro and preclinical investigation.
What is Ipamorelin?
Ipamorelin is a synthetic pentapeptide (five amino acids: Aib-His-D-2-Nal-D-Phe-Lys-NH2) that functions as a selective agonist of the ghrelin receptor, also known as the growth-hormone secretagogue receptor 1a (GHS-R1a). It is one of the most studied compounds in the GHRP (growth-hormone-releasing peptide) class.
Ipamorelin’s defining research characteristic, compared to older GHRPs such as GHRP-2 and GHRP-6, is its selectivity. In published preclinical and clinical research, Ipamorelin has been characterized as activating the ghrelin receptor pathway without causing the cortisol or prolactin elevations associated with the older compounds. This makes it a useful research tool when isolating ghrelin-receptor signaling from off-target hormonal effects.
Ipamorelin is not approved by the FDA for any therapeutic indication. Velora’s product is supplied solely as a research compound for in vitro and preclinical investigation.
Why researchers pair CJC-1295 No DAC with Ipamorelin
The two compounds engage distinct receptor systems on the same target cell population (pituitary somatotrophs), which is the mechanistic basis for the pairing in published research:
- CJC-1295 No DAC: binds the GHRH receptor and is described in research as increasing somatotroph cell readiness to release growth hormone.
- Ipamorelin: binds the ghrelin receptor (GHS-R1a) and is described in research as triggering the actual growth-hormone release event.
- Combined research utility: published preclinical literature describes the GHRH-plus-GHRP combination as producing additive or synergistic effects on GH release magnitude in animal models, compared to either compound alone.
- Pulsatile signaling preserved: the No DAC version of CJC-1295 is paired with Ipamorelin specifically because both compounds have short functional half-lives, preserving the pulsatile signaling pattern that research protocols often aim to model.
All mechanisms above are drawn from peer-reviewed preclinical and in-vitro literature. Velora Research supplies the CJC-1295 No DAC plus Ipamorelin blend solely for further investigation of these and related research questions in laboratory settings.
Key specifications:
| Attribute | CJC-1295 No DAC (5mg) | Ipamorelin (5mg) |
| Alternate research name | Modified GRF 1-29 (ModGRF 1-29) | Ipamorelin acetate |
| Class | Stabilized GHRH analog | Selective ghrelin receptor agonist |
| Receptor target | GHRH receptor | GHS-R1a (ghrelin receptor) |
| Sequence length | 30 amino acids | 5 amino acids (pentapeptide) |
| Sequence | Y-D-A-D-A-I-F-T-Q-S-Y-R-K-V-L-A-Q-L-S-A-R-K-L-L-Q-D-I-L-S-R (modified) | Aib-His-D-2-Nal-D-Phe-Lys-NH2 |
| Molecular formula | C152H252N44O42 | C38H49N9O5 |
| Molecular weight | ~3367.95 g/mol | ~711.86 g/mol |
| CAS number | 863288-34-0 | 170851-70-4 |
| Functional half-life (research) | ~30 minutes | ~2 hours |
| Per-vial amount | 5mg | 5mg |
| Attribute | Specification |
| Combined amount per vial | 10mg total (5mg CJC-1295 No DAC + 5mg Ipamorelin) |
| Form | Lyophilized white powder |
| Combined purity | 99% or higher (HPLC verified per component) |
| Storage (lyophilized) | -20°C, sealed, dry, dark |
| Storage (reconstituted) | 2 to 8°C, single-use aliquots recommended |
| Verification | Independent third-party HPLC and mass spectrometry per batch |
| COA access | Batch-specific COA at verify.janoshik.com (linked from this page) |
Blend pricing:
Velora Research lists the CJC-1295 No DAC plus Ipamorelin blend at a single transparent tier. The blend is sized so a single vial typically covers an entire pilot protocol or a multi-arm cell-culture experiment without re-ordering:
| Vial composition | Price (USD) | Best for |
| 5mg CJC-1295 No DAC + 5mg Ipamorelin (10mg total) | $70.00 | Pilot studies, GH-axis preclinical work, fixed-ratio GHRH plus GHRP protocols |
Free US shipping applies on orders over $200. Most orders process within 1 to 2 business days. International orders are accepted in accordance with applicable research regulations.
Why qualified researchers buy from Velora Research
- Batch-level third-party COA. Each lot of the CJC-1295 No DAC and Ipamorelin components is independently verified before blending, with both purity values reflected on the Certificate of Analysis.
- Mass-spec identity per component. Mass spectrometry confirms the modified-GHRH structure of CJC-1295 No DAC and the pentapeptide structure of Ipamorelin, ruling out substitution risks (oxidized variants, incorrect modifications) that affect lower-grade supply.
- Lot traceability. Each batch is tied to a specific COA accessible by lot number, so any research result can be audited back to the exact verified compound used.
- Fixed-ratio blending. The 1:1 ratio is the most commonly cited blend configuration in published research, making this product a drop-in for protocols that specify this stack without separate reconstitution math.
- US shipping with cold-chain handling. Both peptides are temperature-sensitive in lyophilized form. Velora ships from US fulfillment with 2-day delivery to preserve peptide integrity in transit.
- Compliance-first sales policy. Sales restricted to qualified laboratories, institutions, and research professionals. Research-use-only terms acknowledged at checkout.
Reconstitution and storage guidance (research use)
The CJC-1295 No DAC plus Ipamorelin blend ships as a lyophilized powder containing 5mg of each compound (10mg combined) in a single vial. For in vitro studies, researchers typically reconstitute with bacteriostatic water (0.9% benzyl alcohol) at a concentration matched to the assay protocol.
A common pilot ratio for the 10mg combined vial is 2 mL of bacteriostatic water, yielding a 5 mg/mL stock solution of the combined blend (2.5 mg/mL of each component). Adjust per study design.
- Pre-reconstitution: store sealed at -20°C in a dry, dark environment. Avoid freeze-thaw cycles, which can degrade peptide integrity.
- Post-reconstitution: refrigerate at 2 to 8°C and use within the stability window established by the research protocol. Single-use aliquots reduce repeated exposure to room temperature.
- Handling: reconstitute and aliquot under sterile lab conditions with appropriate PPE.
Velora Research supplies bacteriostatic water as a separate product. Please refer to the peer-reviewed literature for protocol-specific reconstitution and handling parameters.
CJC-1295 No DAC vs. CJC-1295 with DAC
Researchers selecting CJC-1295 for a study often weigh the No DAC version against the DAC version. Summary of how the two differ at the molecular and functional level:
| Attribute | CJC-1295 No DAC | CJC-1295 with DAC |
| Alternate name | Modified GRF 1-29 (ModGRF 1-29) | CJC-1295 DAC |
| Maleimide linker | No | Yes (binds plasma albumin) |
| Functional half-life | ~30 minutes | ~6 to 8 days |
| Signaling pattern | Pulsatile, mimics natural GHRH | Sustained, continuous receptor activation |
| Common pairing | Paired with Ipamorelin or other GHRP for pulse-pattern research | Used alone for sustained-signal research |
| Best for | Studies modeling natural GHRH pulses or GHRH plus GHRP synergy | Studies modeling continuous GHRH signaling |
Velora’s product is the No DAC version, paired with Ipamorelin in the 1:1 configuration used most often in pulse-pattern research.
